European Growth Companies With High Insider Ownership For May 2025

In This Article:

As of May 2025, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising for a fourth consecutive week amid optimism over easing trade tensions between China and the U.S. This positive sentiment is further buoyed by Germany's robust industrial output and recent monetary policy adjustments across several European countries. In such an environment, growth companies with high insider ownership can be particularly appealing to investors seeking alignment between management interests and shareholder value, as these traits may indicate confidence in the company's future prospects amidst evolving market dynamics.

Top 10 Growth Companies With High Insider Ownership In Europe

Name

Insider Ownership

Earnings Growth

Pharma Mar (BME:PHM)

11.8%

43.1%

KebNi (OM:KEBNI B)

38.3%

66.1%

Yubico (OM:YUBICO)

36.5%

30.4%

Bergen Carbon Solutions (OB:BCS)

12%

63.2%

Vow (OB:VOW)

13.1%

81%

Elicera Therapeutics (OM:ELIC)

23.8%

97.2%

CD Projekt (WSE:CDR)

29.7%

37.4%

Elliptic Laboratories (OB:ELABS)

22.6%

51.9%

Norbit (OB:NORBT)

13.2%

26.6%

Nordic Halibut (OB:NOHAL)

29.7%

60.7%

Click here to see the full list of 209 stocks from our Fast Growing European Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Ambu

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ambu A/S is a medical technology company that develops, produces, and sells medical devices to hospitals, clinics, and rescue services globally, with a market cap of DKK27.81 billion.

Operations: The company's revenue is derived from Disposable Medical Products, amounting to DKK5.83 billion.

Insider Ownership: 24.9%

Earnings Growth Forecast: 24.8% p.a.

Ambu A/S demonstrates strong growth prospects with earnings forecasted to increase by 24.8% annually, outpacing the Danish market's 7.7%. Recent financial results show robust performance, with second-quarter sales rising to DKK 1.55 billion and net income reaching DKK 188 million. Despite trading at a discount of 17.6% below its estimated fair value, Ambu's revenue is expected to grow at a rate of 10.2%, surpassing the broader market's pace of 8.2%.

CPSE:AMBU B Earnings and Revenue Growth as at May 2025
CPSE:AMBU B Earnings and Revenue Growth as at May 2025

Surgical Science Sweden

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Surgical Science Sweden AB (publ) specializes in developing and marketing virtual reality simulators for evidence-based medical training globally, with a market cap of SEK7.69 billion.

Operations: The company's revenue is derived from two main segments: Industry/OEM, contributing SEK441.59 million, and Educational Products, accounting for SEK442.50 million.